retatrutide and addiction Why Is Gaining Attention in Peptide Weight Loss Therapy When the Breakthrough Obesity G-Agonist

Here are the public health implications for these new research findings

Overall, nearly one in five (18%) adults now say they have ever used GLP-1 agonist drugs either to lose weight or treat a chronic condition, including 12% who say they are currently using them (an increase of 6 percentage points from May 2024)

Structured meals with specific protein targets per sitting become necessary

UK HealthCare is the hospitals and clinics of the University of Kentucky

Because of the limitations of this type of study, the research cant prove that hormone therapy directly caused the additional weight loss but it supports the idea that estrogen may influence how some women respond to GLP-1s